Phrynoderma: is it an EFA deficiency disease?
The clinical response to various therapeutic agents was evaluated in 31 patients with phrynoderma. A complete clinical response with vitamin B-complex was noted in an average period of 5.7 weeks. In patients treated with vitamin E, partial or total improvement was seen in an average period of 12.3 and 10.7 weeks respectively. Patients treated with safflower oil showed a partial improvement in an average period of 13.2 weeks. The essential fatty acid (EFA) nutriture of 30 patients was compared with 7 controls. Plasma phospholipid fatty acid composition was used as an indicator of EFA nutriture. The patients with phrynoderma fell into two groups. In the 23 children in one group (pattern A), the mean levels of linoleic (18:2 omega 6), arachidonic (20:4 omega 6) and eicosatrienoic (20:3 omega 9) acids were similar to the levels in the controls. The ratio of eicosatrienoic to arachidonic acids (20:3 omega 9/20:4 omega 6), which is considered an accurate measure of EFA nutritional status, was 0.12 and in the normal range, suggesting that the EFA nutriture is normal in phrynoderma. The ratio of linoleic to arachidonic acids (18:2 omega 6/20:4 omega 6) was also found to be normal, suggesting that the metabolism of linoleic to arachidonic acid is not affected in phrynoderma. In seven children in a second group (pattern B), the fatty acid profile was different from patients with pattern A. In these two groups no obvious differences were noted in clinical features and severity. In patients treated with safflower oil, the mean levels of vitamin E were elevated. On all the three treatment schedules, the levels of other fatty acids were not altered. The biochemical and clinical evidence obtained indicate that phrynoderma may not be directly associated with EFA deficiency but that vitamin B-complex may have an important role. The plasma phospholipid fatty acid profile seems to reflect neither the clinical situation nor the response to therapy.
Ghafoorunissa
National Institute of Nutrition, Indian Council of Medical Research, Hyderabad.
Vidyasagar
R
R
Krishnaswamy
K
K
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005228:Fatty Acids, Essential / Q000097:blood / Q000172:deficiency; D005260:Female; D006801:Humans; D007642:Keratosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D009752:Nutritional Status; D010743:Phospholipids / Q000097:blood; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000097:blood; D014810:Vitamin E / Q000008:administration & dosage / Q000097:blood
D005228:Fatty Acids, Essential; D010743:Phospholipids; D014803:Vitamin B Complex; D014810:Vitamin E